Isocitrate dehydrogenase mutations as potential tumour agnostic targets
European Journal of Cancer Supplements · 2026-03 · 17 · 1-10
DOI: 10.1016/j.ejcsup.2025.12.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer Supplements, 2026-03. Verfasst von Teresa Macarulla und 3 weiteren Autor:innen. Beteiligte Einrichtung: Vall d´Hebron University Hospital, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain. Die Arbeit nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Servier.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Vall d´Hebron University Hospital, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain.
- University Hospital Tübingen, Eberhard Karls Universität, Tübingen, Germany.
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- University College London Cancer Institute, London, UK.
- University College Hospital, University College London, London, UK.
Förderung
- Servier
Zitieren
APA
Macarulla, T., Tabatabai, G., Stacchiotti, S., & Bridgewater, J. (2026). Isocitrate dehydrogenase mutations as potential tumour agnostic targets. European Journal of Cancer Supplements, 17, 1-10. https://doi.org/10.1016/j.ejcsup.2025.12.002
Vancouver
Macarulla T, Tabatabai G, Stacchiotti S, Bridgewater J. Isocitrate dehydrogenase mutations as potential tumour agnostic targets. European Journal of Cancer Supplements. 2026;17:1-10. doi:10.1016/j.ejcsup.2025.12.002
BibTeX
@article{Macarulla2026,
author = {Macarulla, Teresa and Tabatabai, Ghazaleh and Stacchiotti, Silvia and Bridgewater, John},
title = {Isocitrate dehydrogenase mutations as potential tumour agnostic targets},
journal = {European Journal of Cancer Supplements},
year = {2026},
volume = {17},
pages = {1--10},
doi = {10.1016/j.ejcsup.2025.12.002}
}
EUVIMED